Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423897 · ClinicalTrials.gov registry record · NA
Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes
A NA study, sponsored by Synbiotic Health.
- Active
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT07423897 is a NA study that is active but no longer recruiting, run by Synbiotic Health. The registered enrollment target is 35 participants.
The verdict
NCT07423897, a NA study, is active but no longer recruiting, sponsored by Synbiotic Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like Klebsiella pneumoniae without adverse effects.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Bifidobacterium pseudocatenulatum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07423897
The ClinicalTrials.gov registry entry for NCT07423897 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synbiotic Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07423897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07423897 about?
NCT07423897 is a clinical study titled "Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes". The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like...
What is the current status of trial NCT07423897?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2026-02-02. Estimated completion is 2026-08-31.
What interventions are being tested in trial NCT07423897?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Bifidobacterium pseudocatenulatum (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07423897?
This trial is sponsored by Synbiotic Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.